Detailed Narrative
Record Revenue and Strong Profitability in Q1 FY26
Advanced Enzyme Technologies achieved its highest-ever quarterly revenue of INR1,859 million in Q1 FY26, marking a 20% year-on-year and 11% quarter-on-quarter growth. This robust top-line performance translated into strong profitability, with EBITDA reaching INR564 million (up 10% YoY, 24% QoQ) and PAT soaring to INR404 million (up 16% YoY, 51% QoQ). The PAT margin stood at a healthy 22% for the quarter, indicating efficient operations despite some margin pressures.
Human and Animal Healthcare Drive Growth
The Human Healthcare segment, the largest contributor, saw its revenue increase by 21% year-on-year to INR1,221 million, now accounting for 65% of total revenue. This growth was primarily driven by strong demand in the pharma/API sector. The Animal Healthcare segment also demonstrated exceptional growth, with revenue rising 51% year-on-year to INR260 million, fueled by increased traction in domestic and Asian markets, and now represents 14% of the total revenue.
Bioprocessing Segment Faces Temporary Dip, Specialized Manufacturing Shows Resilience
The Bioprocessing segment experienced a temporary setback📎, with revenue declining 6% year-on-year and 15% sequentially to INR236 million. This was largely due to a 24% quarter-on-quarter degrowth in the food business. In contrast, the Specialized Manufacturing segment reported INR142 million in revenue, up 29% year-on-year, contributing 7% to the overall revenue, showcasing resilience despite a slight 8% sequential dip.
Strategic Investments in R&D and Sustainability
The company is actively pursuing strategic initiatives, including the establishment of Advanced Nutrazyme Private Limited, a new subsidiary focused on nutrition and wellness products. In its commitment to clean energy, JC Biotech is collaborating with Raywatt Solar Power Systems to meet electricity needs sustainably. R&D spending for the quarter was INR86 million, representing 5% of consolidated revenue, with an additional INR48 crores already invested in a new R&D facility at Nashik, slated for commissioning in the last quarter of FY26.
Gross Margin Pressure and US Tariff Absorption
Gross margins for the quarter were noted to be around 72-73%, lower than the historical range of 75%+, attributed to changes in product mix and the impact of US tariffs. Management confirmed that the 10% US tariff, in effect since April 2025, is currently being absorbed by the company, with an estimated direct impact of INR12-12.5 crores on its INR50 crores US exports. This absorption is a key factor influencing current profitability.
Outlook on Biocatalysts and Long-term Growth
While some commercial sales have commenced in the biocatalysts segment, management indicated that it is still too early to provide a detailed outlook due to global market uncertainties and tariff situations, expecting more clarity in the next 1-2 quarters. Despite these challenges, the company remains optimistic about achieving 'double-digit growth' over the longer run, with current capacity utilization at 60-65% and plans for further expansion once it reaches 80%.